

Steven Brem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5173846/publications.pdf>

Version: 2024-02-01

67
papers

4,995
citations

361413

20
h-index

168389

53
g-index

68
all docs

68
docs citations

68
times ranked

7139
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study. <i>Neuro-Oncology</i> , 2022, 24, 2172-2179.	1.2	15
2	Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	20
3	Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2004-2004.	1.6	10
4	Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2015-2015.	1.6	1
5	Second window ICG predicts gross-total resection and progression-free survival during brain metastasis surgery. <i>Journal of Neurosurgery</i> , 2021, 135, 1026-1035.	1.6	19
6	Enhanced Fiber Tractography Using Edema Correction: Application and Evaluation in High-Grade Gliomas. <i>Neurosurgery</i> , 2021, 89, 246-256.	1.1	6
7	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	7.0	24
8	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 669071.	2.8	34
9	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. <i>Nature Communications</i> , 2021, 12, 3424.	12.8	74
10	Advanced magnetic resonance imaging and spectroscopy in a case of neurocysticercosis from North America. <i>Neuroradiology Journal</i> , 2021, , 197140092110268.	1.2	0
11	Abstract 2203: Identifying the transcriptomic signatures of mutational heterogeneity in GBM using single cell genomics. , 2021, , .		0
12	Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma. , 2021, 12, 337.		5
13	Withdrawn as duplicate: Commentary: "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing. <i>Neurosurgery</i> , 2021, 89, E237-E238.	1.1	0
14	Commentary: "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and Its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing. <i>Neurosurgery</i> , 2021, 89, E262-E263.	1.1	1
15	Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. <i>Scientific Reports</i> , 2021, 11, 15011.	3.3	10
16	Near-Infrared Imaging with Second-Window Indocyanine Green in Newly Diagnosed High-Grade Gliomas Predicts Gadolinium Enhancement on Postoperative Magnetic Resonance Imaging. <i>Molecular Imaging and Biology</i> , 2020, 22, 1427-1437.	2.6	19
17	A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. <i>Cell</i> , 2020, 180, 188-204.e22.	28.9	529
18	Commentary: The Role of Laser Interstitial Thermal Therapy in Surgical Neuro-Oncology: Series of 100 Consecutive Patients. <i>Neurosurgery</i> , 2020, 87, E101-E103.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2020, 79, 843-854.	1.7	32
20	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. <i>JAMA Oncology</i> , 2020, 6, 1939.	7.1	84
21	An additive score optimized by a genetic learning algorithm predicts readmission risk after glioblastoma resection. <i>Journal of Clinical Neuroscience</i> , 2020, 80, 1-5.	1.5	6
22	Freewater estimator using interpolated initialization (FERNET): Characterizing peritumoral edema using clinically feasible diffusion MRI data. <i>PLoS ONE</i> , 2020, 15, e0233645.	2.5	24
23	Commentary: 5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the 2 Techniques to Optimize the Extent of Resection in Glioblastoma Surgery. <i>Neurosurgery</i> , 2020, 86, E541-E543.	1.1	3
24	¹⁸ F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling. <i>Neuro-Oncology Practice</i> , 2020, 7, 152-157.	1.6	14
25	Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. <i>Cancer</i> , 2020, 126, 2625-2636.	4.1	60
26	Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	86
27	Second window indocyanine green localizes CNS lymphoma in real time in the operating room: report of two cases. <i>British Journal of Neurosurgery</i> , 2020, , 1-5.	0.8	4
28	Surface-Registration Frameless Stereotactic Navigation Is Less Accurate During Prone Surgeries: Intraoperative Near-Infrared Visualization Using Second Window Indocyanine Green Offers an Adjunct. <i>Molecular Imaging and Biology</i> , 2020, 22, 1572-1580.	2.6	3
29	NIMG-21. DIFFERENTIATING TUMOR TYPES BASED ON THE PERITUMORAL MICROENVIRONMENT USING CONVOLUTIONAL NEURAL NETWORKS. <i>Neuro-Oncology</i> , 2020, 22, ii151-ii151.	1.2	2
30	NIMG-45. DEEP LEARNING-BASED PERITUMORAL MICROSTRUCTURE MAPPING IN GLIOBLASTOMAS USING FREE WATER VOLUME FRACTION. <i>Neuro-Oncology</i> , 2020, 22, ii157-ii158.	1.2	2
31	NIMG-66. AI-BASED PROGNOSTIC IMAGING BIOMARKERS FOR PRECISION NEUROONCOLOGY AND THE RESPOND CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, ii162-ii163.	1.2	3
32	Tractography and the connectome in neurosurgical treatment of gliomas: the premise, the progress, and the potential. <i>Neurosurgical Focus</i> , 2020, 48, E6.	2.3	84
33	NIMG-39. UTILITY OF PHYSIOLOGIC MR METRICS IN DISTINGUISHING TRUE-PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMAS STRATIFIED BY MGMT PROMOTER METHYLATION. <i>Neuro-Oncology</i> , 2020, 22, ii156-ii156.	1.2	0
34	CTIM-13. CLINICAL EFFICACY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, IN RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED). <i>Neuro-Oncology</i> , 2020, 22, ii35-ii35.	1.2	2
35	IMMU-11. DUAL TARGETING OF IL-6 AND CD40 OVERCOMES GLIOBLASTOMA RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , 2020, 22, ii107-ii107.	1.2	0
36	NIMG-69. PERSONALIZED CONNECTOMIC SIGNATURES: BRIDGING THE GAP BETWEEN NEURO-ONCOLOGY AND CONNECTOMICS. <i>Neuro-Oncology</i> , 2020, 22, ii163-ii163.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0233645.		0
38	Title is missing!. , 2020, 15, e0233645.		0
39	Title is missing!. , 2020, 15, e0233645.		0
40	Title is missing!. , 2020, 15, e0233645.		0
41	Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma. Academic Pathology, 2019, 6, 2374289519848353.	1.1	21
42	Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma. Scientific Reports, 2019, 9, 8747.	3.3	10
43	Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. NMR in Biomedicine, 2019, 32, e4042.	2.8	38
44	Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British Journal of Cancer, 2019, 120, 54-56.	6.4	27
45	Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 141, 421-429.	2.9	15
46	An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability. Molecular Cancer Research, 2019, 17, 1102-1114.	3.4	7
47	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. Journal of Neuro-Oncology, 2019, 141, 95-102.	2.9	5
48	Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI. Journal of Magnetic Resonance Imaging, 2019, 49, 184-194.	3.4	17
49	Evaluating the Association Between the Extent of Resection and Survival in Gliosarcoma. Cureus, 2019, 11, e4374.	0.5	6
50	Recurrent neurenteric cysts compressing the brainstem. , 2019, 10, 245.		1
51	Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2 β . Nature Communications, 2018, 9, 559.	12.8	176
52	2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma. Journal of Clinical and Translational Science, 2018, 2, 45-45.	0.6	0
53	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine, 2018, 16, 142.	4.4	376
54	PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nature Communications, 2018, 9, 3439.	12.8	95

#	ARTICLE	IF	CITATIONS
55	Primary Cell Culture of Live Neurosurgically Resected Aged Adult Human Brain Cells and Single Cell Transcriptomics. <i>Cell Reports</i> , 2017, 18, 791-803.	6.4	60
56	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,116
57	Pervasive within-Mitochondrion Single-Nucleotide Variant Heteroplasmy as Revealed by Single-Mitochondrion Sequencing. <i>Cell Reports</i> , 2017, 21, 2706-2713.	6.4	48
58	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	7.4	1,619
59	Use of targeted next generation sequencing (NGS) to assess mutational load in glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2027-2027.	1.6	1
60	Vessel morphometric parameters-correlation with histologic grade and VEGF expression in oligodendroglioma. <i>American Journal of Cancer Research</i> , 2017, 7, 973-981.	1.4	2
61	Individualized Map of White Matter Pathways. <i>Neurosurgery</i> , 2016, 79, 568-577.	1.1	33
62	Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. <i>CNS Oncology</i> , 2016, 5, 137-144.	3.0	18
63	Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2016, 127, 391-400.	2.9	36
64	Recurrent Glioblastoma. , 2016, , 151-165.		0
65	Factors Associated with Increased Survival after Surgical Resection of Glioblastoma in Octogenarians. <i>PLoS ONE</i> , 2015, 10, e0127202.	2.5	20
66	Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas. <i>Journal of Geriatric Oncology</i> , 2014, 5, 389-399.	1.0	35
67	Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. <i>Cancer</i> , 2013, 119, 3830-3838.	4.1	20